B+
Bull case
20%
Probability
Target price
$0.65
Analysis reference price unavailable
Analysis 2026-08-14 · RankAlpha Sentiment Codex
BIAF
bioAffinityFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
Rapid CyPath Lung volume and physician-adoption growth, ongoing enrollment in an 11-site longitudinal study, and expansion into asthma/COPD diagnostics provide a credible but early commercial and platform-development upside case. [#SEC-8K-2026-08-07]
Posture
Defensive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta -0.0.
What can break
Additional equity financing could create dilution and continued trading overhang.
Momentum
100
Value
41
Sentiment
0
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $0.40 · Bull $0.65 · Bear $0.18Analysis 2026-08-14; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-11 • Model: HYBRID_IC_RP
AI Memo
As of 2026-08-14 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-11
Investment thesis
As of 2026-09-11
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-11. Definitions
Supporting evidence
What
Grade F · Defensive
Confidence Medium · Net Neutral
Why
Momentum100 · Δ7d -
Value41 · Δ7d -0.0
Sentiment0 · Δ7d -
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Confirming evidence
- • Value remains the lead driver in the composite, 7D delta -0.0.
Contradictions & invalidation
- • Additional equity financing could create dilution and continued trading overhang.
- • Clinical validation may not translate into standard-of-care adoption or durable reimbursement.
- • The company remains a roughly $3.1 million market-cap microcap with a small revenue base, financing dependence, clinical-validation risk, and unresolved visibility around Nasdaq minimum-bid compliance identified in the prior baseline.
Catalyst clock
2026-08-13
Recent financing supports execution but adds dilution sensitivity
Lead driver: Value · See fundamentals
Momentum
100
9% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
41
28% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
+0.1
Sentiment
0
62% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade F. Momentum 99.9 / Value 41.2 / Sentiment 0.0
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-08-14. Scenario method
Most likely
B
Base case
50%
Probability
Target price
$0.40
Analysis reference price unavailable
Analysis 2026-08-14 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$0.18
Analysis reference price unavailable
Analysis 2026-08-14 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$3.18M
Beta
2.44
Shares Out
8.1M
P/E (TTM) · Derived
-0.0
P/S (TTM)
0.83
P/FCF (TTM) · Derived
-0.09
Rev YoY
+19.0%
EPS YoY
-87.3%
Gross Margin
+27.6%
Op Margin
-209.8%
Net Debt
-$5.29M
Current Ratio
1.44
As of 2026-09-11 • Updated nightlySource: Internal modelMethods & Data